SCHEMBL367643

SCHEMBL367643

CN(CC1CC1)c1cc(N2CCN(C(=O)OC(C)(C)C)CC2=O)c2nc(C(=O)NCc3ccc(F)cc3)c(OCc3ccccc3)c(=O)n2c1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.39
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
YAP1 P46937 3/20 0.35
HTR2A P28223 1/20 0.34
ENPP2 Q13822 1/20 0.34
LMNA P02545 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE7A Q13946 1/20 0.34
METTL3 Q86U44 1/20 0.34
TLR9 Q9NR96 1/20 0.34
CCNT1 O60563 1/20 0.34
CCNA2 P20248 1/20 0.34
CDK2 P24941 1/20 0.34
CDK9 P50750 1/20 0.34
CCNA1 P78396 1/20 0.34
BACE1 P56817 1/20 0.33
BACE2 Q9Y5Z0 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL367841 0.92 TP53 (0.39) TP53MEN1KMT2AHTR2AENPP2
SCHEMBL10071005 0.92 ENPP2 (0.36) TP53MEN1KMT2AHTR2AENPP2
SCHEMBL15092140 0.89 YAP1 (0.37) MEN1KMT2AYAP1PDE4BPDE7A
SCHEMBL367968 0.88 TP53 (0.42) TP53MEN1KMT2AENPP2LMNA
SCHEMBL15092108 0.87 TP53 (0.40) TP53MEN1KMT2AENPP2LMNA
SCHEMBL368701 0.86 TP53 (0.40) TP53MEN1KMT2AENPP2LMNA
SCHEMBL367233 0.86 TP53 (0.39) TP53MEN1KMT2AHTR2AENPP2
SCHEMBL367642 0.86 TP53 (0.39) TP53MEN1KMT2AYAP1HTR2A
SCHEMBL15101329 0.84 ENPP2 (0.39) TP53MEN1KMT2AHTR2AENPP2
SCHEMBL368957 0.82 TP53 (0.38) TP53MEN1KMT2AENPP2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130178469-A1 NOVEL ANTIVIRAL AGENTS SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (SIOC) (CN) 2013-07-11 US disclosed
EP-2593460-A1 7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS Avexa Limited (AU) 2013-05-22 EP disclosed
WO-2012006680-A1 7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS AVEXA LIMITED (AU) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178469-A1 NOVEL ANTIVIRAL AGENTS EIF2AK2, IFNAR1, IRF3 TP53 3404/4885MEN1 4041/4885KMT2A 3777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.